Atrium Therapeutics, Inc. Common Stock (RNA)
Statistics
Key valuation multiples, financial performance ratios, profitability metrics, and per share data consolidated into a single structured view. Each metric is benchmarked against both industry and sector averages — providing immediate context on whether the company is trading at a premium or discount relative to its direct peers and the broader market segment.
Valuation & Market Metrics
Market Capitalization
141,806,000
EV to revenue ratio (TTM)
491.01
EV to ebitda
-5.72
Financial Performance
Revenue (TTM)
35,837,000
Gross profit (TTM)
-20,200,000
EBITDA
-68,528,000
Profitability
Operating margin (TTM)
-753.00%
Profit margin
-184.10%
Return on assets (TTM)
-399.30%
Return on equity (TTM)
-44.00%
Per Share Metrics
Revenue per share (TTM)
2.1
EPS
-5.43
Diluted EPS (TTM)
-5.43
Book value
12.54
Dividend per share
Dividend yield
Valuation Multiples
P/E ratio
Trailing P/E
Forward P/E
PEG ratio
0
Price to sales ratio (TTM)
3.957
Price to book ratio (TTM)
0.663
Growth
Quarterly earnings growth (YoY)
-21.90%
Quarterly revenue growth (YoY)
0.00%
Analyst Sentiment
Strong buy
0
Buy
3
Hold
0
Sell
0
Strong sell
0
Risk & Volatility
Beta
0.93